Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Rheumatol Int
Hlavní autoři: Kastritis, Efstathios, Kitas, George D., Vassilopoulos, Dimitrios, Giannopoulos, Georgios, Dimopoulos, Meletios A., Sfikakis, Petros P.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7353833/
https://ncbi.nlm.nih.gov/pubmed/32654078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-020-04629-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky